NCT01024010View on ClinicalTrials.gov

Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

September 28, 2017

Conditions
Chronic Lymphocytic LeukemiaStage 0 Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage I Small Lymphocytic LymphomaStage II Chronic Lymphocytic LeukemiaStage II Small Lymphocytic LymphomaStage III Chronic Lymphocytic LeukemiaStage III Small Lymphocytic LymphomaStage IV Chronic Lymphocytic LeukemiaStage IV Small Lymphocytic Lymphoma
Interventions
DRUG

Cyclophosphamide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Ofatumumab

Given IV

DRUG

Pentostatin

Given IV

Trial Locations (4)

27710

Duke University Medical Center, Durham

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER